In addition, it has been observed that MITA is activated by tumor DNAs in APCs to promote type I IFN induction, tumor antigen cross presentation and CD8+ T cell activation and therapeutic activation of MITA results in plausible tumor regression [32]. This evidence concerns the gene CD8A and neoplasm.